|Bid||24.75 x 1000|
|Ask||25.25 x 100|
|Day's Range||24.66 - 26.85|
|52 Week Range||3.85 - 27.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.80|
M&A and deal-making exploding in cell therapy space, demonstrating how important this field will be in the coming 30 to 50 years. Sangamo (SGMO) is the most recent example, with $3 billion deal with ...
NEW YORK, Feb. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Coherent, ...
Sangamo rocketed north of 10% in premarket trading Thursday after landing a deal with Gilead to collaborate on cancer treatments.
The deal is the latest by a major drugmaker looking to develop lucrative gene therapies that have the potential to treat ailments by directly targeting disease-causing genes. Shares of California biotech firm Sangamo jumped more than 20 percent to a 17-year high of $27.30 on Thursday morning. "These are indeed exciting times in the field of genome-editing and gene therapy," Sangamo Chief Executive Officer Sandy Macrae said on a call with analysts.
Gilead Sciences Inc.'s unit Kite has entered an agreement with Sangamo Therapeutics Inc. to collaborate in developing engineered cell therapies to treat cancer. Under the terms of the deal, Kite will use ...
Company Also Separately Announced Collaboration with Kite, a Gilead Company, to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer Conference Call and Webcast at 8:00 a.m. Eastern ...
-- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology -- SANTA MONICA, Calif. and RICHMOND, Calif. , Feb. 22, ...
Kite, a Gilead Company and Sangamo Therapeutics, Inc. today announced the companies have entered into a worldwide collaboration using Sangamo’s zinc finger nuclease technology platform for the development of next-generation ex vivo cell therapies in oncology.
RICHMOND, Calif. , Feb. 20, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the company will release its fourth quarter and full year 2017 financial results before the ...
According to the terms of the agreement, Sangamo Therapeutics will receive an upfront payment of $12 million from Pfizer. Sangamo, using its ZFP-TF platform, will develop ZFP-TF candidates, while Pfizer will undertake operational and financial responsibilities for the further research and development, manufacturing, and commercialization of the ZFP-TF program.
RICHMOND, Calif., Feb. 13, 2018 /PRNewswire/ -- Sangamo Therapeutics (SGMO) yesterday presented preclinical data demonstrating the Company's engineering capabilities in T cell genome editing using zinc finger nucleases (ZFNs). Sangamo Scientist Sumiti Jain, Ph.D. delivered the presentation, "Dual Knock-Out of Endogenous T-Cell Receptor and Human Leukocyte Antigen and Site-Specific Insertion of a CD19-CAR: Implications for Allogeneic T Cell Therapy," at the Keystone Symposium on Emerging Cellular Therapies: T Cells and Beyond. Sangamo's T cell engineering capabilities have advanced rapidly in the last two years with recent improvements to the architecture of zinc finger nucleases (ZFNs).
RICHMOND, Calif., Feb. 12, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the appointment of Heather D. Turner as senior vice president and general counsel, effective immediately. ...
CLEVELAND and RICHMOND, Calif., Feb. 7, 2018 /PRNewswire/ -- Case Western Reserve University and Sangamo Therapeutics, Inc. (SGMO) today announced the award of an $11 million grant from the National Institutes of Health for a planned study of gene-edited T cells designed to eradicate persistent HIV infection in patients receiving anti-retroviral therapy, a combination of medicines that slows the rate at which HIV replicates. The grant will fund a clinical trial to test the hypothesis that treating patients with their own gene-edited T cells may lead to a sustained increase in T cell counts and eradication of latent HIV reservoirs. T cells (so-called because they develop in the thymus gland) are responsible for a variety of immune responses.
RICHMOND, Calif., Feb. 6, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced the presentation of initial safety data from the CHAMPIONS Study, the Phase 1/2 clinical trial evaluating SB-913 for the treatment of mucopolysaccharidosis (MPS) type II, a rare disease also known as Hunter syndrome. The poster presentation titled "Update on phase 1/2 clinical trials for MPS I and MPS II using ZFN-mediated in vivo genome editing" includes safety data collected and prepared as of December 27, 2017 and describes the first six weeks of experience of the first patient in the CHAMPIONS study, who was treated November 13, 2017 with a dose of 5.00E+12 vg/kg of SB-913. The patient tolerated the infusion well. Mild (Grade 1) adverse events related to the study drug were reported on the fourth day after dosing as dizziness, weakness, and frequent urination, all of which resolved within one day without treatment. No other adverse events related to the study drug were observed.